Kelly Long brings to Inotiv over 20 years of pharmaceutical experience in drug discovery, with an emphasis on in vivo pharmacology and toxicology. Long began her career at Monsanto/Pharmacia/Pfizer in 1998 as an in vivo pharmacologist and also functioned as a pharmacology project team leader. She joined Inotiv’s legacy company, Seventh Wave, in 2010 as a study director and has held roles of increasing responsibility in the Inotiv in-life operation, currently leading a cross-site in vivo team in St. Louis and West Lafayette.
Long acts as a consultant, provides cross-site leadership and strategic direction, and fosters cross-site alignment for pharmacology, toxicology, and other in-life-related issues. She is a member of the American College of Toxicology and the Society of Toxicology.